AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines that make a meaningful difference in healthcare. It discovers new medicines that are designed to improve the health and quality of life of patients, offering added benefits such as reduced side effects or better ways of taking the treatment. It focuses on getting the best from every medicine it makes by exploring all the ways it can be used or improved.

AstraZeneca

Yunfeng Capital was established in January 2010. It is the only private equity firm in China set up by successful entrepreneurs, pioneers and industry leaders. Its goal is not merely to be a financial investor, but also to share the entrepreneurial experience with companies, helping them refine their development, organizational management and brand building strategies.  Yunfeng Capital places a special emphasis on young entrepreneurs, grooming future leaders to lead world-class enterprises. Yunfeng is the result of combining the Chinese first names of Mr. Jack MA (Yun), Chairman of Alibaba, and Mr. David YU (Feng), Founder of Target Media.  In addition, there are more than 10 other co-founders, including Mr. Yu Zhu SHI, Chairman of Giant interactive group, Mr. Yong Hao LIU, Chairman of New Hope Group, Mr. Guo Jun SHEN, Chairman of Intime Investment, Mr. Yu Suo WANG, Chairman of ENN Group, Mr. Jason JIANG, Chairman of Focusmedia, Mr. Hang XU, Chairman of Shenzhen Mindray Medical, Mr. Yi Hong CHEN, Chairman of China Dongxiang(Group), Mr. Xin ZHOU, Chairman of E-House (China), Mr. Jian Guo WANG, Founder of Fivestar, Mr. Shao Xiong ZHOU, Chairman of Septwolves, Mr. Xu Ning WANG, Chairman of Joyong Holdings, Mr. You Cai ZHANG, President of Unifront Holdings.  Yunfeng Capital is headquartered in Shanghai. Branch offices are located in Hong Kong, Beijing, Hangzhou, and other mainland cities.

YF Capital

HongShan is a VC firm focused on seed-stage, mid-stage, late-stage, and growth investments in the fintech sector. HongShan has offices in Hong Kong, Beijing, Shanghai, Guangzhou, Hangzhou, Suzhou, and Shenzhen. Over the past nine years, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models, including Alibaba, VIPshop.com, Sina.com, Didi, JD.com, Ourpalm, Qihoo 360, Jumei, Momo, SINNET, Dianping.com, Meituan, Meilishuo, Toutiao, AutoNavi, Ganji.com, DJI, VanceInfo, Noah Private Wealth Management, Wanda Cinemas, Alibaba Pictures, Plateno Hotels Group, Deppon Logistics, ZTO Express, Beta Pharma, Snibe Diagnostic, BGI, WEGO, and Yuwell Medical.

HongShan

GIC is a global investment firm established in 1981 to manage Singapore's foreign reserves. A disciplined long-term value investor, GIC is uniquely positioned for investments across a wide range of asset classes, including equities, fixed income, private equity, real estate, and infrastructure. GIC invests through funds and directly in companies, partnering with its fund managers and management teams to help world-class businesses achieve their objectives. In tech investing, GIC seeks to be a lifetime partner to the companies it invests in. GIC has investments in over 40 countries around the world. Headquartered in Singapore, GIC employs over 1,700 people across 10 offices in key financial cities worldwide.

TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.

TF Capital

Cellular Biomedicine Group

Cellular Biomedicine Group is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. It is the result of the acquisition, transfer, commercialization, and advancement of thirty years of research and human treatment experience in cellular medicine. Its cellular research and development is the result of collaboration among scientists and doctors from the US, England, and China.

AbelZeta Pharma (previously known as Cellular Biomedicine Group) develops cell-based therapies in the fields of oncology and immunology. The company uses chimeric antigen receptor T cells (CAR-T cells), armored CAR-T cells, and tumor-infiltrating lymphocytes therapies (TIL therapies) for its treatment solutions. AbelZeta Pharma notes that it has facilities across the US, England, and China, for carrying out clinical trials as well as producing its cell therapy solutions.&nbsp;

Novel therapies to reboot cells and organs

Cell & Gene Therapy

AbelZeta Pharma

Cellular Biomedicine Group Announces FDA Clearance of IND Application for Novel TIL Therapy C-TIL051

Janssen

To develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

Chimeric antigen receptor T-cell (CAR-T) therapy involves genetically engineering T cells to target and kill cancer cells

AbelZeta Pharma (previously known as Cellular Biomedicine Group) develops cell-based therapies in the fields of oncology and immunology. The company uses chimeric antigen receptor T cells (CAR-T cells), armored CAR-T cells, and tumor-infiltrating lymphocytes therapies (TIL therapies) for its treatment solutions. AbelZeta Pharma notes that it has facilities across the US, England, and China, for carrying out clinical trials as well as producing its cell therapy solutions.&nbsp; As of May 2024, AbelZeta had a total of ten therapeutic&nbsp; candidates. Four were being developed for hematology-related malignancies,&nbsp; one for autoimmune diseases, and five for solid tumor indications. As of the same date, Its lead candidate, C-Car039 for the treatment of relapsed or refractory B-cell lymphoma was in the Phase 1/1B clinical testing stage.&nbsp; Key customers and partnerships AbelZeta Pharma, then Cellular Biomedicine, signed a collaboration agreement with Janssen Biotech and Cellular Biomedicine Group In May 2023 to develop and manufacture CAR-T cell therapies for the treatment of B-cell malignancies. Through the partnership, Jansen would pay an upfront fee of USD 245 million, with additional milestone payments, based on agreeing to allow Jansen to license CBG’s CAR-T assets for treating B-cell malignancies globally, excluding China.

<div>
 
 Tenaya Therapeutics is a developer of therapeutics for heart disease. The company develops its therapeutics using precision medicine, gene therapy, and cellular regeneration. Tenaya produces therapeutics that also use proprietary in-vivo and in-vitro models. Additionally, the company has developed in-house adeno-associated virus (AAV) capsid engineering capabilities and has screened over one billion variants from more than 30 diverse, proprietary AAV libraries. The company is publicly listed on the Nasdaq and trades under the ticker symbol TNYA.&nbsp;&nbsp;
 
 
 In October 2023 Tenaya Therapeutics (Tenaya) received FDA clearance for the company&rsquo;s investigational new drug application (TN-401) to initiate clinical testing. TN-401 is Tenaya&rsquo;s adeno-associated virus serotype 9-based investigational gene therapy drug candidate for the treatment of arrhythmogenic right ventricular cardiomyopathy caused by mutations in the plakophilin-2 gene. 
 
 
 As of May 2024, the company&rsquo;s clinical pipeline included two candidates in Phase I clinical trials, a gene therapeutic for the treatment of Hypertrophic Cardiomyopathy, and a small molecule inhibitor for the treatment of heart failure with preserved ejection fraction. Additionally, Tenaya had one gene therapy candidate and two genetic medicine candidates in preclinical testing phases, along with five genetic medicine candidates in the discovery stage. 
 
 
 
</div>

Tenaya Therapeutics

<div>
 
 Sarepta Therapeutics is a gene therapy provider for conditions such as Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy 
 (LGMD), and Charcot-Marie-Tooth Disease. The company&rsquo;s therapeutics incorporate technology related to gene therapy, RNA technologies, and gene editing. The company leverages a proprietary phosphorodiamidate morpholino oligomer (PMO) platform for the development of its RNA-based therapeutics. As of August 2023, the company had four FDA-approved treatments for DMD: ELEVIDYS, EXONDYS 51, VYONDYS 53, and AMONDYS 45. Sarepta Therapeutics is also listed on the Nasdaq, trading under the symbol SRPT.&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 As of May 2024, the company had several RNA, gene, and gene editing therapeutics in various clinical stages. Sarepta had two RNA therapeutics, both for the treatment of DMD, one in clinical testing, and the other in pre-clinical testing. Additionally, the company had six gene therapeutics, one for the treatment of DMD (both in clinical testing), four for the treatment of LGMD (three in clinical testing, one in preclinical testing) and one for multiple targets (in preclinical testing). Also, Sarepta had two gene editing-based therapeutics in development for the treatment of DMD, both in preclinical testing phases. 
 
 
 
 
 Key customers and partnerships
 
 
 
 
 Over the years since its founding, Sarepta has partnered with several industry and academic partners. The list includes Dyno Therapeutics, Genethon, Genevant Sciences, Hansa Biopharma, Roche, Columbia University, Harvard University, Translational Laboratory of Murdoch University, University of Florida College of Medicine, The Abigail Wexner Research Institute at Nationwide Children&rsquo;s Hospital, University of Massachusetts Medical School, and the University of Western Australia.&nbsp;&nbsp;
 
 
 
 
 In October 2021, Sarepta and healthcare giant Roche announced they would collaborate on carrying out a clinical study of Sarepta&rsquo;s therapeutic candidate SRP-9001 for the treatment of DMD.&nbsp;
 
 
 
 
 Sarepta and pharmaceutical company Catalent announced that in January 2023, the companies were signing a commercial supply agreement. Through the agreement,&nbsp; Catalent would manufacture Sarepta&rsquo;s gene therapeutic for the treatment of DMD; delandistrogene moxeparvovec (SRP-9001).
 
 
 
</div>

Sarepta Therapeutics

<div>
 
 Mesoblast is a cell therapy manufacturer that provides therapeutics for oncology, cardiovascular, orthopedic, hematology, immunity, and inflammation-related conditions. The company is listed on the Australian Stock Exchange and trades under the ticker symbol &ldquo;MSB.&rdquo; Mesoblast develops therapeutics using its proprietary mesenchymal lineage cell technology platform, which is used to produce cryopreserved, off-the-shelf, and cellular-based solutions. The company also incorporates 3D bioreactor technology and automation into its production process to produce higher yields.&nbsp;
 
 
 
 
 As of May 2024, the company had five candidates that are in various stages of clinical testing. Mesoblast&rsquo;s steroid-refractory candidate for Acute Graft Versus Host Disease is currently in late-stage Phase III clinical testing and is the closest candidate to commercialization. The company&rsquo;s drug candidates for acute respiratory distress syndrome, chronic low back pain, and chronic heart failure and reduced ejection fraction are also in Phase III clinical testing while its candidate for inflammatory bowel disease is in Phase II of clinical testing.&nbsp;
 
 
 
 
 Key customers and partnerships
 
 
 
 
 The company has secured several agreements with international companies with regard to development and commercialization of Mesoblast&rsquo;s candidates, including Gr&uuml;nenthal GmBH, JCR Pharmaceuticals, Tasly Pharmaceutical Group, TiGenix NV, and the Lonza Group.&nbsp;
 
 
 
 
 Additionally, in April 2020, Mesoblast partnered with The US NIH&rsquo;s National Heart, Lung, and Blood Institute to conduct testing of its allogeneic mesenchymal stem cell (MSC) product candidate, &ldquo;remestemcel-L.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 
</div>

Mesoblast

<div>
 
 Ocugen is a gene therapy manufacturer that develops vaccine, cell, and gene-based therapeutics for infectious, eye, and orthopedic diseases. Its cell therapy includes a three dimensional tissue-engineered cartilage disk through the growth of chondrocytes &ndash; the cells responsible for maintaining cartilage health. Its gene therapy solution consists of creating a copy of the patient&rsquo;s gene in order to replace mutated/damaged genes. The company is publicly listed on the Nasdaq, and trades under the symbol &lsquo;OCGN&rsquo;.&nbsp;
 
 
 As of May 2024, the company had five therapeutic solutions being clinically tested. The company was developing four gene therapies for the treatment of retinitis pigmentosa, Leber congenital amaurosis, geographic atrophy, and orphan disease. Its treatment candidate for retinitis pigmentosa was in Phase III of clinical study, while its other gene therapies were in Phase I/II. 
 Ocugen was also developing a biological material, in the IND stage, for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. The company's cell therapy for the treatment of articular cartilage defects in the knee was in Phase III of clinical study. Finally, the company was also developing three vaccines, all in IND stages, for prevention of diseases caused by the flu, Covid-19, and a combination of the flu and Covid-19.
 
 
 Key customers and partnerships
 
 
 Ocugen partnered with biopharmaceutical manufacturer Jubilant HollisterStier of Spokane in June 2021 to manufacture its Covid-19 therapeutic COVAXIN. Through the partnership, Jubilant would be the potential commercial manufacturer of Ocugen&rsquo;s vaccine for the US and Canadian markets.
 
 
 
 
 
</div>

Ocugen

<div>
 
 MeiraGTx is a developer of gene therapies that aim to treat ocular diseases and problems, neurodegenerative disorders, and salivary gland and autoimmune disorders. MeriaGTx is also developing riboswitch-inducible expression programs for the treatment of inherited obesity and Wilson disease, along with producing small-molecule riboswitch inducers. The company is listed on the Nasdaq and trades under the symbol MGTX.&nbsp;&nbsp;
 
 
 As of May 2024, the company had four gene-based therapeutic candidates in Phase II of their clinical trials for the treatment of (1) xerostomia, Parkinson's Disease, and RPE65-Associated retinal dystrophy and (2) achromatopsia. The company also had one therapeutic being developed to treat Sjogren&rsquo;s Syndrome that was in Phase I/II of its clinical trials. Additionally, MeiraGTx had seven other therapeutics in discovery/preclinical stages. The company was also developing a therapeutic for X-linked retinitis pigmentosa in collaboration with Janssen, which was in Phase III of clinical trials. 
 
 
 Key customers and partnerships
 
 
 MeiraGTx partnered with the International Institute of Risk and Safety Management (IIRSM) in November 2022 to influence risk agendas, raise awareness, the standards of risk, and safety management across the industry.&nbsp;
 
 
 Funding and financials
 
 
 Meira last raised funds in October 2023, when the company secured a strategic investment of USD 30 million from Sanofi. As part of the transaction, Sanofi was granted the right of first negotiation for MeiraGTx's gene regulation technology in certain targets.&nbsp;
 
 
 
</div>

MeiraGTx

Companies producing cells, genes, tissues, and biomaterials such as exosomes and extracellular matrix for drug developers and pharmaceutical companies developing regenerative medicine

Companies conducting R&D on therapies that modify or introduce new genes into the body to treat diseases

Includes therapies that use cells (other than CAR-T and stem cells) such as Adipose-Derived Regenerative Cells (ADRCs), cardiosphere-derived cells, and gamma delta T cells (GDT cells)

Stem cell therapy involves using stem cells usually extracted from the bone marrow and umbilical cord blood to repair a variety of diseases

Startups in the hub consider individual patient profiles, involving variability in genes, environment, and lifestyle

Genomics helps understand the genetic information stored in the DNA to develop targeted treatments

AbelZeta Pharma

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless